Breast Ca Mortality Decline Greatest in Younger ER+ Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 4
Volume 16
Issue 4

A new study shows that recent declines in breast cancer mortality rates have been most significant among women with estrogen-receptor (ER)-positive tumors and women younger than age 70

BETHESDA, Maryland—A new study shows that recent declines in breast cancer mortality rates have been most significant among women with estrogen-receptor (ER)-positive tumors and women younger than age 70 (J Clin Oncol published online April 2, 2007). Between 1990 and 2003, breast cancer mortality rates declined by 24%. The researchers found that among women under age 70, mortality declined 38% for those with ER-positive tumors vs 19% for ER-negative tumors, and among women 70 or older, by 14% for ER-positive tumors vs no decline for ER-negative tumors.

"These trends since 1990 are likely attributable to at least two factors: the use of tamoxifen after surgery . . . and widespread use of screening mammography, which is more likely to detect the slow-growing tumors that tend to be ER-positive," said lead author Ismail Jatoi, MD, PhD, of the Uniformed Services University of the Health Sciences.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content